Lundbeck sues IP Australia, Sandoz to escape undertaking over Lexapro licence

Clayton Utz 2019-04-09 4:44 pm By Miklos Bolza | Sydney

Please login to bookmark

Global pharmaceutical giant Lundbeck has launched a bid to escape a prior undertaking blocking it from appealing a court’s decision that allowed four generic drug makers to apply for licences to manufacture generic versions of popular antidepressant Lexapro.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au